HHS Unveils Initiative to Accelerate U.S. Clinical Trials
HHS has launched a broad, department-wide initiative (Operation TrialBlazer) aimed at speeding clinical research, reducing regulatory barriers, and attracting more clinical trials back to the U.S. A centerpiece of the initiative is a new FDA proposal to establish a pilot program designed to shorten the timeline between drug discovery and first-in-human Phase 1 clinical trials. The agency will also be clarifying regulatory expectations for sponsors in ways that could reduce early-stage development timelines by six to 12 months, according to HHS.
The effort, announced by HHS secretary Robert F. Kennedy Jr., brings together multiple agencies across the department, including FDA, National Institutes of Health, Advanced Research Projects Agency for Health, and the Office of the National Coordinator for Health Information Technology, in what officials described as an effort to restore America's position as the world's leading location for biomedical innovation. FDA has created a separate Web page on its activities related to the iniative.
"America should be the best place in the world to develop new medicines, yet we have built a system that drives too much clinical research overseas," Kennedy said in a statement.
In a related move, FDA is issuing a new draft guidance articulating how in many cases a single well-controlled late-stage clinical trial accompanied by confirmatory evidence could provide sufficient evidence of effectiveness to support drug approval. The policy is intended to reduce development burdens while maintaining scientific standards, it says.
NIH is announcing several initiatives aimed at improving trial efficiency, including expanded use of artificial intelligence, real-world data, human cell-based models, and practical clinical trial tools. The agency said these approaches could help accelerate the development of new therapies without compromising scientific rigor.
Within NIH, the National Center for Advancing Translational Sciences will build on lessons learned from the development of the first personalized CRISPR-based gene-editing treatment to accelerate future rare disease programs. Meanwhile, the National Cancer Institute is working with cancer centers and researchers to streamline trial activation and improve patient enrollment in oncology studies.
The Office of the National Coordinator for Health Information Technology is exploring ways to connect patients with clinical trials through electronic health records, potentially allowing eligible individuals to learn about research opportunities during routine clinical care.
Additionally, HHS Office of Inspector General is seeking public input on potential changes to federal anti-kickback safe harbor regulations and beneficiary inducement rules that may affect patient participation in clinical trials.
HHS said the coordinated effort is intended to reduce unnecessary delays, strengthen domestic research capacity, expand patient participation in studies, and ensure that more medical breakthroughs are developed in the United States. The department also called on industry, academic medical centers, contract research organizations, healthcare providers, and patient groups to help identify and eliminate barriers that slow clinical research.
During his recent tenure, former FDA commissioner Marty Makary emphasized broader concerns about U.S. competitiveness in drug development, particularly in early-stage clinical research. He noted that China has overtaken the U.S. in Phase 1 clinical trial activity in recent years, with significantly faster timelines for initiating studies. He had previously discussed many of the issues just announced in the HHS initiative. (see earlier story).